{"filing":{"accession_number":"0001193125-26-365556","cik":"0002100782","ticker":"GENB","company_name":"Generate Biomedicines, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"ck0002100782-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2100782/000119312526365556/ck0002100782-20260825.htm"},"events":[{"id":29577,"run_id":27086,"accession_number":"0001193125-26-365556","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Generate Biomedicines disclosed that draft clinical trial posters for its lead candidate GB-0895 were inadvertently made publicly available via the ERS website prior to the embargo expiration. The company proactively furnished the final posters as Exhibit 99.1 to ensure accurate disclosure of ongoing Phase 1 and Phase 3 trial data for asthma and COPD indications. This is a material operational/disclosure event involving clinical trial data for a development-stage biotech company, though the company's precautionary measure mitigates the severity.","company_name":"Generate Biomedicines, Inc.","ticker":"GENB","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31900,"accession_number":"0001193125-26-365556","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Generate Biomedicines disclosed that draft clinical trial posters for its lead candidate GB-0895 were inadvertently made publicly available via the ERS website prior to the embargo expiration. The company proactively furnished the final posters as Exhibit 99.1 to ensure accurate disclosure of ongoing Phase 1 and Phase 3 trial data for asthma and COPD indications. This is a material operational/disclosure event involving clinical trial data for a development-stage biotech company, though the company's precautionary measure mitigates the severity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:04:41.675677+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31900,"accession_number":"0001193125-26-365556","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Generate Biomedicines disclosed that draft clinical trial posters for its lead candidate GB-0895 were inadvertently made publicly available via the ERS website prior to the embargo expiration. The company proactively furnished the final posters as Exhibit 99.1 to ensure accurate disclosure of ongoing Phase 1 and Phase 3 trial data for asthma and COPD indications. This is a material operational/disclosure event involving clinical trial data for a development-stage biotech company, though the company's precautionary measure mitigates the severity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T10:04:41.675677+00:00","company_name":"Generate Biomedicines, Inc.","ticker":"GENB","filing_date":"2026-08-25"}]}